6α/β-Naltrexamine Analogues for Selective MOR Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid addiction treatments, such as naltrexone and naloxone, suffer from severe side effects due to lack of selectivity for Mu opioid receptors (MOR) over other opioid receptors, and existing selective MOR antagonists have limitations like irreversible binding or poor bioavailability and blood-brain barrier penetration.
Innovation Solution
Development of novel non-peptidyl, selective, and reversible MOR antagonists, specifically 6 α/β-naltrexamine analogues, designed through homology modeling and synthesized to exhibit high selectivity for MOR with improved bioavailability and blood-brain barrier penetration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If naltrexone and naloxone are used to treat opioid addiction, then opioid craving is curbed and relapse is prevented, but severe side effects occur due to lack of selectivity for MOR over other opioid receptors
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural modifications (6α/β-naltrexamine analogues with indole substituents at position 17) that confer selective affinity for MOR. The molecular structure is locally optimized to interact preferentially with MOR binding site characteristics, achieving selectivity ratios of KOR/MOR > 100 and DOR/MOR > 100, thereby producing MOR-specific therapeutic effects while avoiding activation of other opioid receptors that cause side effects
2Object-affected harmful factors
If selective MOR antagonists such as β-FNA and clocinnamox are used, then selectivity for MOR is improved, but irreversible binding to MOR limits their use as drugs
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure from irreversible binding modes to reversible binding modes through specific functional group arrangements in the 6α/β-naltrexamine indole analogues. The compounds maintain high MOR selectivity (KOR/MOR > 100, DOR/MOR > 100) while exhibiting reversible binding characteristics with appropriate dissociation kinetics for clinical use, thus changing the binding parameter from irreversible to reversible
3Object-affected harmful factors
If conformationally constrained peptides such as CTOP and CTAP are used, then high selectivity for MOR is achieved, but limited bioavailability and poor blood-brain barrier penetration capacity make them unsuitable as drug development candidates
Solution Approach 1:
The patent applies mechanics substitution by replacing the peptidyl (protein-based) structure with a non-peptidyl small molecule structure (6α/β-naltrexamine indole analogues). This substitution maintains the selective MOR binding capability while dramatically improving pharmacokinetic properties including oral bioavailability and blood-brain barrier penetration, as small molecules generally have better membrane permeability and metabolic stability compared to peptides
Data Source
Figure 1A~1D
Figure 2A~2C
Figure 3A~3C
AI summary
Analogues of 6 α/β-naltrexamine (NAQ) are provided. The analogues are selective, reversible antagonists of the mu opioid receptor (MOR) that exhibit good blood brain barrier penetration. The compounds are used in the treatment of opioid addiction and other diseases and conditions, including for the treatment of pain.